paracetamol administration
PreclinicalSmall molecule
paracetamol administration is one of 7 small molecule programs targeting Hemodynamic. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Hemodynamic
#DrugCompanyPhaseTrials
1Gnrh Ant
Merck & Co.Phase 3
Xylocaine
MMEDRx USA, Inc.
Preclinical
Diphenhydramine Hcl
RochePreclinical
Crystalloid
KKonkuk University Medical Center
Preclinical
Urapidil
UUniversity Hospital, Strasbourg, France
Preclinical
Colloid
SSahlgrenska University Hospital
Preclinical
paracetamol administration
CCentre Hospitalier Universitaire de Nice
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hemodynamic1 trial
Hemodynamic Impact of the Administration of PAracetamol in Patients Hospitalized in the Intensive Resuscitation Medicine Department [PAREA]
Not yet recruiting·—·N/A·NCT06430697·200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for paracetamol administration. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details